Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Breast cancer diagnosis and staging in Chile: A non-randomized survey-based study to assess frequency and delays Diagnóstico y etapificación de cáncer de mama en Chile: estudio por encuesta no probabilística de III a IV frecuencia y tiempos
Indexado
WoS WOS:001362789700001
Scopus SCOPUS_ID:85206278522
DOI 10.5867/MEDWAVE.2024.09.2801
Año 2024
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



INTRODUCTION Breast cancer progression involves physiological mechanisms such as metastasis. Delays in diagnosis and treatment increase the risk of mortality and are associated with barriers to healthcare access. In Chile, breast cancer is highly prevalent, and early diagnosis has improved, although disparities in the disease evolution persist. This study characterized diagnostic and staging tests, waiting times, and sociodemographic profiles to identify delays and inequities in care. METHODS Survey study. Using a non-probabilistic sample, a questionnaire was applied in an encrypted platform with prior informed consent. The instrument collected data on requested tests, associated times, staging, and sociodemographic characteristics. These variables were analyzed using descriptive statistics, tests of association, confidence intervals, and comparison tests using bootstrapping. RESULTS A sample of 263 persons was obtained. The most requested tests were biopsy (99.62%) and blood tests (80.23%). The median number of tests requested was six (Q1:4, Q3:8), with a mean of 5.87 (standard deviation: 2.24). No significant differences were observed in the percentage of persons from whom the total number of examinations were requested according to the studied variables. The day-hour-result intervals ranged from 1 to 365 days. The median day-hour-result of the biopsy was 15 days (Q1:10, Q3:30). People between 40 and 49 years old, non-residents of the capital city, belonging to income quintile I, with high school education, from the public health system, with late-stage diagnosis had higher median day-hour-result in biopsy. There was no significant difference in the number of requested tests according to staging (I and II, or III and IV). CONCLUSIONS Biopsy in Chile is the test of choice for diagnostic confirmation in breast cancer. Other tests are requested regardless of the diagnosis stage, contrary to the recommendations of clinical guidelines. Cancer prognosis is crucial, especially in countries with greater inequalities.

Revista



Revista ISSN
Medwave 0717-6384

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Medicine, General & Internal
Scopus
Medicine (All)
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Campana, Carla Mujer Universidad del Desarrollo - Chile
2 Galvez, Marcela Oyarte Mujer Inst Salud Publ Chile - Chile
Instituto de Salud Pública de Chile - Chile
3 CABIESES-VALDES, BALTICA BEATRIZ - Universidad del Desarrollo - Chile
Ctr Prevenc & Control Canc - Chile
4 Obach, Alexandra Mujer Universidad del Desarrollo - Chile
Ctr Prevenc & Control Canc - Chile
Centro para la Prevención y Control del Cáncer (CECAN) - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Agencia Nacional de Investigación y Desarrollo
Chilean Center for Cancer Prevention and Control
CECAN
Centro para la Prevención y Control del Cáncer de Chile
Doctoral Program in Science and Innovation in Medicine, Universidad del Desarrollo

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
The authors express their gratitude to Patients, cancer patient organizations, and health institutions for their contribution in recruitment, the Doctoral Program in Science and Innovation in Medicine, Universidad del Desarrollo, and the Chilean Center for Cancer Prevention and Control (CECAN), ANID FONDAP 152220002 ANID Chile. Funding Project funded by the Centro para la Prevenci\u00F3n y Control del C\u00E1ncer de Chile (CECAN), ANID FONDAP 152220002 ANID Chile.

Muestra la fuente de financiamiento declarada en la publicación.